June 22, 2024

Recombinant Antibodies Market Size to Cross USD 23.34 Bn by 2033

The global recombinant antibodies market size reached USD 12.40 billion in 2023 and is projected to hit around USD 23.34 billion by 2033 growing at a CAGR of 6.53% from 2024 to 2033.

Recombinant Antibodies Market Size 2024 to 2033

Key Points

  • North America dominated the market with the largest share in 2023.
  • By type, the single-chain antibody segment dominated the market in 2023.
  • By application, the pharmaceutical & biotechnology segment held the largest share of the market in 2023 and the segment is expected to sustain the position throughout the forecast period.

Report Summary

The global recombinant antibodies market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the recombinant antibodies market across the globe.

A comprehensive estimate on the recombinant antibodies market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of recombinant antibodies during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3889

Recombinant Antibodies Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 6.53%
Global Market Size in 2023 USD 12.40 Billion
Global Market Size by 2033 USD 23.34 Billion
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Type and By Application
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized recombinant antibodies market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Automotive Embedded Telematics Market Size Will be USD 99.78 Bn by 2033

Market Players

The report includes the profiles of key recombinant antibodies market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Recent Developments

  • In November 2023, the novel GS Effex® cell line from Lonza was introduced to facilitate the production of therapeutic antibodies with increased potency. The GS Effex® cell line was created in response to urgent market demands brought on by the move toward more advanced therapeutic antibodies. GS Effex®, which is derived from Lonza’s top-performing GS Xceed® cell line, integrates well with Lonza platforms. When coupled with robust cell growth and the capacity to generate potent therapeutic antibodies, this unique cell line offers a solution for therapeutic development spanning from early-stage research to commercial manufacture. The Fc domains produced by this scalable, stable, and prolific cell line are fucose-free, increasing the therapeutic efficacy and function of the final antibody that is used in antibody-dependent cellular cytotoxicity (ADCC).
  • In April 2023, the mAbModsTM chimeric anti-mouse PD1 and PD-L1 recombinant antibodies are designed to target mouse-programmed cell death receptor 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) in vivo functional studies. Leinco Technologies is a biotechnology company that specializes in producing antibodies, recombinant proteins, ELISA kits, and second-step reagents. These are the first of a planned series of mouse anti-mouse antibodies that will be introduced in the upcoming months. They are intended to reduce the immunogenicity issues that arise when employing antibodies from non-mouse species in mouse-based investigations, especially when the usage of the antibodies is protracted. These species include rats and hamsters.
  • In August 2023, a new COVID-19 monoclonal antibody therapy for the prevention of SARS-CoV-2 infection is being supported in its clinical development, clinical manufacturing, and regulatory licensure process by Regeneron Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority (BARDA). The deal is a component of the U.S. Department of Health and Human Services (HHS) “Project NextGen,” which aims to develop a pipeline of novel COVID-19 vaccines and treatments.

Recombinant Antibodies Market Companies

  • Abnova
  • BBI Solutions
  • F. Hoffmann-La Roche
  • BIOLEGEND
  • BD Biosciences
  • Creative Biolabs
  • Merck KGaA
  • Bio-Rad Laboratories
  • Abcam
  • SinoBiological
  • GE Healthcare
  • ProMab Biotechnologies
  • Beckman Coulter

Segments Covered in the Report

By Type

  • Chimeric Antibody
  • Full Human Antibody
  • Humanized Antibody
  • Single Chain Antibody
  • Bispecific Antibody

By Application

  • Pharmaceutical & Biotechnology
  • Hospitals & Diagnostic Laboratories
  • Research Institutes
  • Others

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Recombinant Antibodies Market 

5.1. COVID-19 Landscape: Recombinant Antibodies Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Recombinant Antibodies Market, By Type

8.1. Recombinant Antibodies Market, by Type, 2024-2033

8.1.1. Dipeptidyl

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Full Human Antibody

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Humanized Antibody

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Single Chain Antibody

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Bispecific Antibody

8.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Recombinant Antibodies Market, By Application

9.1. Recombinant Antibodies Market, by Application, 2024-2033

9.1.1. Pharmaceutical & Biotechnology

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Hospitals & Diagnostic Laboratories

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Research Institutes

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2021-2033)

 

Chapter 10. Global Recombinant Antibodies Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Type (2021-2033)

10.1.2. Market Revenue and Forecast, by Application (2021-2033)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Type (2021-2033)

10.1.3.2. Market Revenue and Forecast, by Application (2021-2033)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Type (2021-2033)

10.1.4.2. Market Revenue and Forecast, by Application (2021-2033)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Type (2021-2033)

10.2.2. Market Revenue and Forecast, by Application (2021-2033)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Type (2021-2033)

10.2.3.2. Market Revenue and Forecast, by Application (2021-2033)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Type (2021-2033)

10.2.4.2. Market Revenue and Forecast, by Application (2021-2033)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Type (2021-2033)

10.2.5.2. Market Revenue and Forecast, by Application (2021-2033)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Type (2021-2033)

10.2.6.2. Market Revenue and Forecast, by Application (2021-2033)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Type (2021-2033)

10.3.2. Market Revenue and Forecast, by Application (2021-2033)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Type (2021-2033)

10.3.3.2. Market Revenue and Forecast, by Application (2021-2033)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Type (2021-2033)

10.3.4.2. Market Revenue and Forecast, by Application (2021-2033)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Type (2021-2033)

10.3.5.2. Market Revenue and Forecast, by Application (2021-2033)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Type (2021-2033)

10.3.6.2. Market Revenue and Forecast, by Application (2021-2033)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Type (2021-2033)

10.4.2. Market Revenue and Forecast, by Application (2021-2033)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Type (2021-2033)

10.4.3.2. Market Revenue and Forecast, by Application (2021-2033)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Type (2021-2033)

10.4.4.2. Market Revenue and Forecast, by Application (2021-2033)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Type (2021-2033)

10.4.5.2. Market Revenue and Forecast, by Application (2021-2033)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Type (2021-2033)

10.4.6.2. Market Revenue and Forecast, by Application (2021-2033)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Type (2021-2033)

10.5.2. Market Revenue and Forecast, by Application (2021-2033)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Type (2021-2033)

10.5.3.2. Market Revenue and Forecast, by Application (2021-2033)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Type (2021-2033)

10.5.4.2. Market Revenue and Forecast, by Application (2021-2033)

Chapter 11. Company Profiles

11.1. Abnova

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. BBI Solutions

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. F. Hoffmann-La Roche

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. BIOLEGEND

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. BD Biosciences

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Creative Biolabs

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Merck KGaA

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Bio-Rad Laboratories

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Abcam

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. SinoBiological

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com


Prathamesh

Leave a Reply

Your email address will not be published. Required fields are marked *